Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
IPSC Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IPSC Stock 12 Month Forecast
Average Price Target
$4.50
▲(782.35% Upside)
| Highest Price Target$7.00 | Average Price Target$4.50 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$7
Buy
1272.55%
Upside
Reiterated
09/03/25
Analysts Offer Insights on Healthcare Companies: HCW Biologics (NASDAQ: HCWB) and Century Therapeutics (NASDAQ: IPSC)We believe CNTY-101 (allogeneic CD19-CAR- iNK cell) is a differentiated product for autoimmune disease (AID) given its strong safety profile and, potentially, reduced lymphodepletion (LD) requirements. However, with enrollment still lagging (first patient dosed in March, two patients dosed as of 2Q), we believe 2H35 updates will not be substantive. There are also several confounders that could reduce the interpretability of this first readout: diverse set of AID indications, use of low- dose IL-2 on alternating patients, heterogeneity in number of CNTY-101 cycles, and geographic diversity. Enrollment difficulties are not unique to IPSC, and the company's efforts to refocus R&D spend provide sufficient runway to capture a more stock-moving dataset in 2026.
H.C. Wainwright
$2
Buy
292.16%
Upside
Reiterated
08/19/25
Piper Sandler
$2
Buy
292.16%
Upside
Reiterated
05/16/25
Chardan Capital
$11→$7
Buy
1272.55%
Upside
Reiterated
03/24/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$7
Buy
1272.55%
Upside
Reiterated
09/03/25
Analysts Offer Insights on Healthcare Companies: HCW Biologics (NASDAQ: HCWB) and Century Therapeutics (NASDAQ: IPSC)We believe CNTY-101 (allogeneic CD19-CAR- iNK cell) is a differentiated product for autoimmune disease (AID) given its strong safety profile and, potentially, reduced lymphodepletion (LD) requirements. However, with enrollment still lagging (first patient dosed in March, two patients dosed as of 2Q), we believe 2H35 updates will not be substantive. There are also several confounders that could reduce the interpretability of this first readout: diverse set of AID indications, use of low- dose IL-2 on alternating patients, heterogeneity in number of CNTY-101 cycles, and geographic diversity. Enrollment difficulties are not unique to IPSC, and the company's efforts to refocus R&D spend provide sufficient runway to capture a more stock-moving dataset in 2026.
H.C. Wainwright
$2
Buy
292.16%
Upside
Reiterated
08/19/25
Piper Sandler
$2
Buy
292.16%
Upside
Reiterated
05/16/25
Chardan Capital
$11→$7
Buy
1272.55%
Upside
Reiterated
03/24/25
Best Analysts Covering Century Therapeutics
1 Month
xxx
Success Rate
8/21 ratings generated profit
Average Return
-3.06%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 38.10% of your transactions generating a profit, with an average return of -3.06% per trade.
3 Months
xxx
Success Rate
5/21 ratings generated profit
Average Return
-6.36%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 23.81% of your transactions generating a profit, with an average return of -6.36% per trade.
1 Year
Success Rate
3/21 ratings generated profit
Average Return
-42.16%
reiterated a buy rating 24 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -42.16% per trade.
2 Years
xxx
Success Rate
1/21 ratings generated profit
Average Return
-69.98%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 4.76% of your transactions generating a profit, with an average return of -69.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IPSC Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
10
6
3
1
2
Buy
0
0
0
0
0
Hold
4
7
10
10
6
Sell
4
3
1
1
1
Strong Sell
0
0
0
0
0
total
18
16
14
12
9
Each month's total comprises the sum of three months' worth of ratings.
IPSC Financial Forecast
IPSC Stock Forecast FAQ
What is IPSC’s average 12-month price target, according to analysts?
Based on analyst ratings, Century Therapeutics’s 12-month average price target is 4.50.
What is IPSC’s upside potential, based on the analysts’ average price target?
Century Therapeutics has 782.35% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IPSC a Buy, Sell or Hold?
Century Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Century Therapeutics’s price target?
The average price target for Century Therapeutics is 4.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $2.00. The average price target represents 782.35% Increase from the current price of $0.51.
The highest analyst price target is $7.00 ,the lowest forecast is $2.00. The average price target represents 782.35% Increase from the current price of $0.51.
What do analysts say about Century Therapeutics?
Century Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of IPSC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.